Table 1.
Patient and tumor characteristics
| Patient ID (#) | Primary tumor | Known somatic variant (nucleotide change) | Variant allele frequency in tissue (%) |
|---|---|---|---|
| BP‐001 | NSCLC | KRAS p.G12C (c.34G>T) | 32 |
| BP‐003 | Melanoma | NRAS p.Q61R (c.182A>G) | 88 |
| BP‐004 | Melanoma | BRAF p.V600E (c.1799_1800delinsAA) | 50 |
| BP‐007 | Melanoma | BRAF p.V600K (c.1798_1799delGTinsAA) | 38 |
| BP‐008 | CRC | KRAS p.G12D (c.35G>A) | 45 |
| BP‐009 | CRC | PIK3CA p.E545K (c.1633G>A) | 45 |
| BP‐015 | CRC | KRAS p.G13D (c.38G>A) | 40 |
| BP‐016 | CRC | KRAS p.G12V (c.35G>T) | Unknown |
| BP‐023 | CRC | KRAS p.G13D (c.38G>A) | Unknown |
| BP‐028 | Melanoma | BRAF p.V600K (c.1798_1799delinsAA) | 55 |
CRC, colorectal cancer; NSCLC, non‐small‐cell lung cancer.